Actively Recruiting
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Led by Scott C. Woller, MD · Updated on 2024-07-17
152000
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
Sponsors
S
Scott C. Woller, MD
Lead Sponsor
J
Janssen Pharmaceuticals
Collaborating Sponsor
AI-Summary
What this Trial Is About
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.
CONDITIONS
Official Title
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Discharging clinician must be a physician, nurse practitioner, or physician assistant in hospitalist, internal medicine, or family medicine roles
- Patient age 18 years or older
- The patient encounter must be an inpatient stay
- A signed hospital discharge order must be present
- Patient must meet criteria for increased venous thromboembolism risk and low bleeding risk
You will not qualify if you...
- Patient is pregnant during the hospital encounter
- Discharge order completed by clinician not in eligible roles
- Patient is actively prescribed and intended to be discharged on anticoagulant medications including apixaban, dabigatran, dalteparin, enoxaparin, edoxaban, betrixaban, fondaparinux, rivaroxaban, or warfarin
- Estimated creatinine clearance is less than 30 milliliters per minute based on the last available serum creatinine value
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Intermountain Medical Center
Murray, Utah, United States, 84107
Actively Recruiting
Research Team
V
Valerie Aston, MBA
CONTACT
C
Carlos Barbagelata, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here